For Private Equity
Identify clinical adoption, manufacturing, and regulatory risks with our physician and biomedical engineer-led framework. Quick Score from $2,500 (24h). Full Platform DD from $175,000 (3–4 weeks).
Batch Pipeline Screening
Watch Vantage transform an unscored pipeline into ranked, actionable intelligence
| Company | Score | Status |
|---|
Competitive Advantage
50% faster. 60% less expensive. 100% quantitative.
What We Find
Clinical adoption as primary risk
Single-source supplier risk
Write-down rate (unvalidated reimbursement)
Risk stratification accuracy
Will physicians change workflow? We assess adoption barriers invisible to financial DD.
Design-for-manufacturing gaps and supplier integration risks remain invisible until scale-up.
Predicate strategies that won't survive FDA scrutiny. Typical remediation: 12-18 months + $1-3M.
Devices with unclear payer pathways fail post-FDA approval. We map pricing viability.
Cross-category pattern intelligence validated across 2,000+ documented outcomes.
Single-payer reliance = existential risk. We model coverage change impact.
Pricing
Start rapid, scale deep — with physician-engineer support at every stage
Typical PE workflow: Most PE clients start with a Vantage Score to validate target fit and quantify clinical risks, then escalate to PE Platform DD for deals that advance to late-stage evaluation or integration planning. Platform DD pricing scales with transaction complexity and scope. Contact us for a scoped proposal.
Also available: Bolt-On DD ($95K), Portfolio Triage ($25–30K/company), Annual Retainer ($350K/year). Post-close surveillance scoped custom.
Companies that skip clinical-technical due diligence face an average 3.2x higher write-down rate.
Deal Integration
Risk intelligence from deal sourcing through post-close monitoring
Portfolio screening to identify clinical and manufacturing risks early
Rapid triage on target profile and strategic fit
Full assessment with IC-ready report and questions
Board-ready presentation with risk quantification
Integration checkpoints and portfolio risk tracking
How we'd diligence a platform
Each card is a public retrospective, not a private case. The point is to show the framework: what we'd score, what we'd flag, and what an LP would have seen pre-deal.
Polyethylene packaging defect, 200K+ implants recalled, $1.5B liability, Chapter 11. Walks the manufacturing-control and complaint-trend signals a platform DD would have caught.
Read the retrospective →FDA warning letter forced a category change post-IPO, halting US sales for 18 months. The classification risk was knowable from public filings predating the deal.
Read the retrospective →First FDA-cleared prescription digital therapeutic, $1.6B SPAC, bankruptcy in 24 months. Traces the payer-coverage and prescribing-economics signals available at deal time.
Read the retrospective →Custom platform DD ($175K) and bolt-on DD ($95K) are scoped per deal — confidentiality precludes named client work until a sponsor authorizes attribution.
Stay ahead of portfolio risk after close. PE Annual Retainer from $350,000/year (up to 6 assessments + quarterly reviews) for active platform investors. Post-close surveillance programs are scoped per portfolio on a custom basis.
Learn About Enterprise Programs →Start with Quick Score to triage deal flow. Engage our team for full due diligence on finalists.
The 15 regulatory, clinical, and commercial red flags that kill healthcare deals — written by Dr. Arvind Ravinutala (MD) and Aswini Ravinutala (BME).
Download the GuideNo email required. No paywall.